Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
-
Recombinant Collagen Repair Mask
Contact UsCOLLAGEN SUPPLEMENTATION – A SCIENTIFIC SOLUTION TO AGING SKIN
-
JA Solar Deep Blue 3.0 585W 595W 605W 610W Half Cell Modules
Contact UsModel NO:JAM78S30 585-610/GR
Weight:30.5 kg
Transport Package:Wooden Pallet and Carton Packing
Specification:2456±2mm*1134±2mm*35±1mm
Trademark:JA solar
Origin:China -
An ideal climate with Powerful units K48UXR-727P
Contact Us● Powerful units with high cooling and heating capacity
● Lightweight design, intelligent design
● Longer battery life, meeting the need for a full night’s sleep
● Energy saving/lightweight/quiet
● Split structure, bottom mounted
● Energy saving and low consumption, quality assurance
● The company has passed the automotive industry IATF16949 certification
Reviews
There are no reviews yet.